FLT3

Assoc. Prof. Jessica K. Altman | 2017 ASCO Annual Meeting | Molecular response to gilteritinib, a FLT3 inhibitor, in R/R AML, FLT3+

Anne Villeneuve Stephanie Hill , Jun 8, 2017 , Expert Opinion

2017 ASCO Annual Meeting - 2-6 June, Chicago

Download this article:

You can now download this article in Adobe PDF^® format.

Download as PDF

Professional society

The European LeukemiaNet (ELN) is a non-profit charitable organisation funded by donations and based on an established network of excellence where clinicians and scientists improve therapy options for leukemia patients worldwide. The ELN addresses every individual and all groups dedicated to fight leukemia - from medical doctors, researchers, healthcare professionals, patients and their relatives to private and public organisations and charities.